Conmed (NASDAQ: CNMD) reported Q4 EPS of $0.84, $0.08 better than the analyst estimate of $0.76. Revenue for the quarter came in at $252.8 million versus the consensus estimate of $262.94 million.

GUIDANCE:

Conmed sees FY2021 EPS of $2.85-$3.05, versus the consensus of $3.02. Conmed sees FY2021 revenue of $975-1020 million, versus the consensus of $1020 million.

For earnings history and earnings-related data on Conmed (CNMD) click here.